Product Overview
[Drug Name]
Generic Name: Nifedipine Controlled-Release Tablets
Trade Name: Beiqikang Nifedipine Controlled-Release Tablets 30mg x 21 Tablets
Pinyin Code: BeiQiKang XiaoBenDiPingKongShiPian 30mg x 21 Tablets
[Main Ingredient]
The main ingredient of this product is nifedipine. Chemical Name: 2,6-Dimethyl-4-(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate. Molecular Formula: C₁ₐH₁₈N₂O₆. Molecular Weight: 346.34
[Properties]
This product is a pink film-coated tablet. After removal of the coating, a reddish-brown and light yellow double-layer tablet core is revealed.
[Indications/Main Functions]
1. Hypertension 2. Chronic Stable Angina (Exertional Angina) in Coronary Artery Disease
[Specifications]
30mg x 21 tablets
[Dosage and Administration]
Treatment should be tailored to individual needs whenever possible. Different baseline doses are administered based on the patient's clinical condition. Unless otherwise directed by a physician, the following dosage is recommended for adults: 1. Hypertension: The recommended dose is 30 mg (1 tablet) once daily. If necessary, the dose can be increased to 60 mg (2 tablets) once daily based on individual needs. 2. Coronary Artery Disease: The usual initial dose for chronic stable angina (exertional angina) is 30 mg (1 tablet) once daily. If necessary, the dose can be increased to 60 mg (2 tablets) once daily based on individual needs. Nifedipine dose adjustment or omission may be necessary when coadministered with CYP3A4 inhibitors or inducers (see [Drug Interactions]). Treatment duration: The duration of medication should be determined by the physician. Dosage: The tablet should generally be swallowed whole with a small amount of liquid, regardless of mealtime. Grapefruit juice should be avoided (see [Drug Interactions]). Patients with mild, moderate, or severe hepatic impairment (as measured by the Child-Pugh score) should be carefully monitored and may require a dose reduction. The pharmacokinetics of nifedipine have not been studied in patients with severe hepatic impairment (see [Precautions] and [Pharmacokinetics]).
[Adverse Reactions]
See the package insert for details.
[Contraindications]
· This product is contraindicated in patients with a known hypersensitivity to nifedipine or any of its ingredients. Nifedipine is contraindicated in cardiogenic shock. · It is contraindicated in patients with a KOCK pouch (ileostomy after proctocolectomy). · Due to enzyme induction, effective plasma concentrations of nifedipine are not achieved when used concomitantly with rifampin. Therefore, it should not be used concomitantly with rifampin. · Nifedipine is contraindicated in women under 20 weeks of pregnancy and during lactation.
[Precautions]
See the package insert for details.
